Molecular Glue Redirects Cancer Protein to Trigger Cell Death in Lymphoma
A novel two-part molecule created by scientists at Stanford Medicine has shown promise in targeting a key protein involved in B-cell lymphoma, a type of blood cancer. The molecule works by altering the protein鈥檚 function, shifting it from encouraging cell growth to triggering cell death.
The treatment, which involves administering the molecule twice daily for a short period, was tested in mice with aggressive lymphoma tumors. Within 11 days, the tumors were significantly reduced, according to the study.
Researchers describe the molecule as acting like a ‘molecular glue,’ binding to the protein and changing its behavior. This approach could offer a new strategy for treating cancers driven by similar proteins, though further studies are needed to confirm its effectiveness in humans.
The findings highlight the potential of targeting protein interactions to combat cancer, but experts caution that translating these results into clinical applications will require additional research and testing.
Based on reporting from Medical Xpress (Cancer).
Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.
